Revvity, Inc. (NYSE:RVTY) reported stronger-than-expected results for the second quarter, with steady revenue gains across its Life Sciences and Diagnostics segments, despite a complex economic backdrop.
The company delivered adjusted earnings per share of $1.18, beating Wall Street expectations of $1.14. Total revenue reached $720 million, exceeding the average analyst forecast of $710.39 million. Compared to the same quarter last year, when revenue stood at $692 million, this marked a 4% increase on a reported basis and 3% organic growth.
Following the announcement, shares of Revvity edged up by 1.2%, reflecting investor confidence in the company’s operational momentum.
“The power of Revvity’s transformation and consistent execution were evident in our second-quarter performance, enabling us to exceed expectations despite the evolving market environment,”
said Prahlad Singh, president and chief executive officer of Revvity.
The Life Sciences unit led the performance, generating $366 million in revenue, up 5% year-over-year (4% organically). Meanwhile, the Diagnostics business recorded $354 million, representing a 3% increase (2% organically) compared to the same period last year.
Despite the revenue gains, adjusted operating income dipped slightly to $192 million, down from $199 million a year earlier. The adjusted operating margin also declined, from 28.8% to 26.6%.
Looking ahead, Revvity raised its full-year revenue guidance to a range of $2.84 to $2.88 billion, translating to 2–4% organic growth. The company now anticipates full-year earnings per share between $4.85 and $4.95, with the midpoint just shy of analyst consensus at $4.93.
The company cited robust innovation efforts and a disciplined execution strategy as key contributors to its performance, reinforcing its focus on delivering long-term value despite ongoing macroeconomic headwinds.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.